Pharmacokinetics of Aztreonam in Healthy Elderly and Young Adult Volunteers
Pharmacokinetics of Aztreonam in Healthy Elderly and Young Adult Volunteers
复制标题
DOI：
10.1002/j.1552-4604.1993.tb04690.x
复制
发表时间：
1993-05
期刊：
影响因子：
--
通讯作者：
B. Meyers;P. Wilkinson;M. Mendelson;C. Bournazos;Carmelita Tejero;S. Hirschman
中科院分区：
文献类型：
--
作者：
B. Meyers;P. Wilkinson;M. Mendelson;C. Bournazos;Carmelita Tejero;S. Hirschman
氨曲南是一种单菌素，其抗菌谱与氨基糖苷类相似，具有抗需氧革兰氏阴性杆菌的活性，是唯一可用于对β-内酰胺类药物过敏的患者的相关药物。比较了氨曲南在两组健康志愿者体内的药代动力学。青年组包括10名年龄在18岁至30岁之间的成年人，老年组包括10名65岁以上的成年人。两组分别给予氨曲南两剂(1g和2g)，间隔1周。虽然两组的氨曲南平均血药浓度峰值相似，但其他药动学参数存在差异。例如，对于2-g剂量，年轻组的平均半衰期(1.80±0.51vs3.1±.9h)和曲线下面积(AUC)(294.42±64.08vs469.01±144.02μg×小时/毫升/1.73m2)低于老年组。年轻组氨曲南的平均全身清除量大于老年组。结果与1-g剂量下的药动学参数相似。这些结果反映了在老年组中发现的较低的肌酐清除量和较高的血清肌酐水平。这些数据表明，在老年人群中，较低剂量的氨曲南以较少的频率间隔给药可能是合适的。
Aztreonam is a monobactam exhibiting an antibacterial spectrum similar to that of the aminoglycosides, with activity against aerobic gram‐negative bacilli, and is the only related drug that may be given to patients hypersensitive to beta‐lactams. The pharmacokinetics of aztreonam were compared in two groups of healthy volunteers. The young group comprised 10 adults between the ages of 18 and 30 years, and the elderly group included 10 adults older than 65 years of age. The two groups each received two doses (1 and 2 g) aztreonam, separated by 1 week. Although the mean peak serum concentrations of aztreonam for the two groups were similar, there were differences in other pharmacokinetic parameters. For example, for the 2‐g dose the mean half‐life (1.8 ± .51 versus 3.1 ± .9 hour), and area under the curve (AUC) (294.42 ± 64.08 versus 469.01 ± 144.02 μg × hour/mL per 1.73 m2) were less for the younger group compared with the elderly group. The mean total body clearance of aztreonam was greater for the younger than the elderly group. The results were similar to the pharmacokinetic parameters derived from the 1‐g dose. These results mirror the lower creatinine clearances and higher serum creatinine levels found in the elderly group. The data suggest that lower doses of aztreonam given at less frequent intervals may be appropriate in the elderly population.